RenovoRx closes $11.1M private placement; total 2024 raise $17.2M, funds Phase III trial into 2026

RenovoRx, Inc.

Gross proceeds of $11.1M from private placement of common stock, pre-funded, Series A, B, and placement agent warrants.
Net proceeds estimated at ~$9.6M; total gross proceeds raised in 2024 now $17.2M from two placements.
Issued 6,960,864 common shares, pre-funded warrant for 951,500 shares, Series A/B warrants for 7.9M and 3.96M shares.
Proceeds for working capital, Phase III TIGeR-PaC trial in LAPC, and pipeline expansion into additional cancer indications.
Company expects cash runway into 2026; second interim analysis for TIGeR-PaC estimated in late 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.